Albrecht H - Search Results

1

Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.

Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ. Natarajan A, et al. Among authors: albrecht h. Bioconjug Chem. 2005 Jan-Feb;16(1):113-21. doi: 10.1021/bc0498121. Bioconjug Chem. 2005. PMID: 15656582

2

Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.

Albrecht H, Denardo GL, Denardo SJ. Albrecht H, et al. Q J Nucl Med Mol Imaging. 2007 Dec;51(4):304-13. Epub 2007 May 1. Q J Nucl Med Mol Imaging. 2007. PMID: 17464275 Free article. Review.

3

Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.

Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn KR, Venclovas C, Colvin ME, Burke PA, DeNardo GL. Winthrop MD, et al. Among authors: albrecht h. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3845S-53S. Clin Cancer Res. 2003. PMID: 14506182

4

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.

Albrecht H, Burke PA, Natarajan A, Xiong CY, Kalicinsky M, DeNardo GL, DeNardo SJ. Albrecht H, et al. Bioconjug Chem. 2004 Jan-Feb;15(1):16-26. doi: 10.1021/bc030018+. Bioconjug Chem. 2004. PMID: 14733579

5

Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.

Albrecht H, Denardo GL, Denardo SJ. Albrecht H, et al. J Immunol Methods. 2006 Mar 20;310(1-2):100-16. doi: 10.1016/j.jim.2005.12.012. Epub 2006 Feb 3. J Immunol Methods. 2006. PMID: 16499921

6

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: albrecht h. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s. doi: 10.1158/1078-0432.CCR-1004-0013. Clin Cancer Res. 2005. PMID: 16203820

7

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ. Burke PA, et al. Among authors: albrecht h. Int J Oncol. 2006 Jul;29(1):49-55. Int J Oncol. 2006. PMID: 16773184

8

Recombinant antibodies: from the laboratory to the clinic.

Albrecht H, DeNardo SJ. Albrecht H, et al. Cancer Biother Radiopharm. 2006 Aug;21(4):285-304. doi: 10.1089/cbr.2006.21.285. Cancer Biother Radiopharm. 2006. PMID: 16999595 Review.

9

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.

Albrecht H, Cosman M, Ngu-Schwemlein M, Corzett M, Curran KW, Dolan C, Fang X, DeNardo SJ, DeNardo GL, Balhorn R. Albrecht H, et al. Cancer Biother Radiopharm. 2007 Aug;22(4):531-42. doi: 10.1089/cbr.2007.375A. Cancer Biother Radiopharm. 2007. PMID: 17803448

10

111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.

Denardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, Anderson C, Peng L, Ferdani R, Cherry SR, Lam KS. Denardo SJ, et al. Among authors: albrecht h. J Nucl Med. 2009 Apr;50(4):625-34. doi: 10.2967/jnumed.108.056903. Epub 2009 Mar 16. J Nucl Med. 2009. PMID: 19289419 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

583 results

Search Page

Filters